College of American pathologists conference XXXI on laboratory monitoring of anticoagulant therapy: The clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban

Archives of Pathology and Laboratory Medicine

Volumn 122, Issue 9, 1998, Pages 799-807

  Laposata, Michael ^a   Green, David ^b   Van Cott, Elizabeth M ^a   Barrowcliffe, Trevor W ^c   Goodnight, Scott H ^d   Sosolik, Randolph C ^e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e Southern Ohio Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ARDEPARIN; ARGATROBAN; DALTEPARIN; DANAPAROID; DESULFATOHIRUDIN; ENOXAPARIN; HEPARIN DERIVATIVE; HIRUDIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN;

ANTICOAGULANT THERAPY; BLEEDING; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DRUG INDICATION; DRUG MECHANISM; DRUG MONITORING; GOOD LABORATORY PRACTICE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MEDICAL LITERATURE; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; PARTIAL THROMBOPLASTIN TIME; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA;

EID: 0031680310     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (117)

1. Barrowcliffe TW, Johnson EA, Thomas DP. Low Molecular Weight Heparin. New York, NY: John Wiley & Sons; 1992:209.
2. Bara L, Bilaud E, Gramond G, Kher A, Samama M. Comparative pharmacokinetics of low molecular weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. Thromb Res. 1985;39: 631-636.
3. Lane DA. Heparin binding and neutralizing proteins. In: Heparin: Chemical and Biological Properties: Clinical Applications. London: E. Arnold; 1989;17: 363-391.
4. Barzu T, Molho P, Tobelem G, et al. Binding and endocytosis of heparin by human endothelial cells in culture. Biochim Biophys Acta. 1985;845:196-203.
5. Young E, Wells P, Holloway S, Weitz J, Hirsh J. Ex-vivo and in vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost. 1994;71:300-304.
6. Mason L, Rischke J, Young E, Hirsh J. Administration of no affinity heparin in vivo alters the tissue localization and metabolism of unfractionated heparin. Blood. 1995;86:881. Abstract.
7. Hirsh J, Levine MN. Low molecular weight heparin. Blood. 1992;79:1-17.
8. Frydman A, Bara I, Leroux Y, et al. The antithrombotic activity and pharmacokinetics of enoxaparin, a low molecular weight heparin in humans given single subcutaneous doses of 20 to 80 mg. J Clin Pharmacol. 1988;28:609-618.
9. Rosenberg RD, Bauer KA. The heparin-antithrombin system: a natural anticoagulant mechanism. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 3rd ed. Philadelphia, Pa: Lippincott; 1994:837-860.
10. Danielsson A, Raub E, Lindahl U, Bjork I. Role of ternary complexes in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa. J Biol Chem. 1986; 261:15467-15473.
11. Norrheim L, Abildgaard U, Larsen ML, Lindahl AK. Involvement of the extrinsic pathway in the activities of low molecular weight heparins. Thromb Res. 1991;14(suppl):19-27.
12. Green D, Hirsh J, Heit J, Prins M, Davison B, Lensing AWA. Low molecular weight heparin: a critical analysis of clinical trials. Pharmacol Rev. 1994;46:89-109.
13. Lensing AWA, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low molecular weight heparins: a meta analysis. Arch Intern Med. 1995;155:601-607.
14. Geerts WH, Jay RM, Code KI, et al. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med. 1996;335:701-707.
15. Clagett GP, Anderson FA, Heit J, Levine MN, Wheeler HB. Prevention of venous thromboembolism. Chest. 1995;108(suppl):312S-334S.
16. Green D, Lee MY, Lim AC, et al. Prevention of thromboembolism after spinal cord injury using low-molecular-weight heparin. Ann Intern Med. 1990; 113:571-574.
17. Firsc Investigators. Low-molecular-weight heparin during instability in coronary artery disease. Lancet. 1996;347:561-568.
18. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med. 1997;337:447-452.
19. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med. 1997;337:657-662.
20. Simonneau G, Sors H, Charbonnier B, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med. 1997;337:663-669.
21. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996;334:677-681.
22. Koopman MMW, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med. 1996;334:682-687.
23. Kay R, Wong KS, Yu YL, et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med. 1995;333:1588-1593.
24. Hunt BJ, Doughty HA, Majumdar G, et al. Thromboprophylaxis with low molecular weight heparin (Fragmin) and high risk pregnancies. Thromb Haemost. 1997;77:39-43.
25. Bergquist D, Benoni G, Bjorgell O, et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med. 1996;335:696-700.
26. Pini M, Aiello S, Manotti C, et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost. 1994;72:191-197.
27. Walsh-McMonagle D, Green D. Low-molecular-weight heparin in the management of Trousseau's Syndrome. Cancer. 1997;80:649-655.
28. Leizorovicz A, Simonneau G, Decousus H, Boissel JP. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis. BMJ. 1994;309: 299-304.
29. Hirsh J, Siragusa S, Cosmi B, Ginsberg JS. Low molecular weight heparins (LMWH) in the treatment of patients with acute venous thromboembolism. Thromb Haemost. 1995;74:360-363.
30. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med. 1992;326:975-982.
31. Weitz JI, Hirsh J. New anticoagulant strategies. J Lab Clin Med. 1993;122: 364-373.
32. Greinacher A, Potzach B, Amiral J, et al. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost. 1994;71:247-251.
33. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular weight heparin or unfractionated heparin. N Engl J Med. 1995;332:1330-1335.
34. Shaughnessy SG, Young E, Deschamps P, Hirsh J. The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria. Blood. 1995;86:1368-1373.
35. Monreal M, Lafoz E, Olive A, del Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost. 1994;72:7-11.
36. Melissari E, Parker CJ, Wilson NV, et al. Use of low molecular weight heparin in pregnancy. Thromb Haemost. 1992;68:652-656.
37. Anderson DR, O'Brien BJ, Levine MN, et al. Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty. Ann Intern Med. 1993;119: 1105-1112.
38. Hull RD, Raskob GE, Rosenbloom D, et al. Treatment of proximal vein thrombosis with subcutaneous low-molecular intravenous heparin: an economic perspective. Arch Intern Med. 1997;157:289-294.
39. Cadroy Y, Pourrat J, Baladre MF, et al. Delayed elimination of enoxaparin in patients with chronic renal insufficiency. Thromb Haemost. 1991;63:385-390.
40. Boneu B. Low molecular weight heparin: is monitoring needed? Thromb Haemost. 1994;72:330-334.
41. Goudable C, Saivin S, Houin G, et al. Pharmakokinetics of a low molecular weight heparin (Fraxiparine®) in various stages of chronic renal failure. Nephron. 1991;59:543-545.
42. Massicotte P, Adams M, Marzinotto V, Brooker LA, Andrew M. Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study . J Pediatr. 1996;128:313-318.
43. Harenberg J, Giese Ch, Dempfle CE, Stehle G, Heene DL. Biological activity and safety of the subcutaneous administration of high doses of low molecular weight heparin for 8 days in human volunteers. Thromb Haemost. 1989;61: 357-362.
44. Collignon F, Frydman A, Caplain H, et al. Comparison of the pharmacokinetic profiles of three low molecular mass heparins - daltepaarin, enoxaparin and nadroparin - administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost. 1995;73:630-640.
45. Samama MM. Contemporary laboratory monitoring of low molecular weight heparins. Clin Lab Med. 1995;15:119-123.
46. Sie P, Aillaud MF, de Prost D, et al. Measurement of low molecular weight heparin ex vivo activities in clinical laboratories using various anti Xa assays: interlaboratory variability and requirement of an agreed low molecular weight heparin standard. Thromb Haemost. 1987;58:879-883.
47. Barrowcliffe TW. Low molecular weight heparins. Br J Haematol. 1995;90: 1-7.
48. Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood. 1991;78:2337-2343.
49. Simonneau G, Charbonnier B, Decousus H, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch Intern Med. 1993;153:1541-1546.
50. Agnelli G, Iorio A, Renga C, et al. Prolonged antithrombin activity of low-molecular-weight heparins. Circulation. 1995;92:2819-2824.
51. Lindmarker P, Holstrom M, Granquist S, lohnsson H, Lockner D. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost. 1994;72:186-190.
52. Alhenc-Gelas M, Guernic JL, Vitoux JF, et al. Adjusted versus fixed doses of the low-molecular-weight heparin Fragmin in the treatment of deep vein thrombosis. Thromb Haemost. 1994;71:698-702.
53. Holstrom MC, Berglund S, Granquist G, Bratt G, Tornebohm E, Lockner D. Fragmin once or twice daily subcutaneously in the treatment of deep venous thrombosis of the leg. Thromb Res. 1992;67:49-55.
54. Handeland GF, Abildgaard U, Holm HA, Arnesen KE. Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Eur J Pharmacol. 1990;39:107-112.
55. National Committee for Clinical Laboratory Standards. Collection, Transport, and Processing of Blood Specimens for Coagulation Testing and Performance of Coagulation Assays. 2nd ed. Approved guideline. Villanova, Pa: NCCLS; 1991 NCCLS document H21-A2.
56. Ozawa T, Domagalski J, Mammen E. Determination of low molecular weight heparin by Heptest on the automated coagulation system. Am J Clin Pathol. 1993;99:157-162.
57. Ortel TL, Gockerman JP, Califf RM, et al. Parenteral anticoagulation with the heparinoid Lomoparan (Org 10172) in patients with heparin induced thrombocytopenia and thrombosis. Thromb Haemost. 1992;67:292-296.
58. de Valk HW, Banga JD, Wester JWJ, et al. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. Ann Intern Med. 1995;123:1-9.
59. Danhof M, de Boer A, Magnani HN, Stiekema JC. Pharmacokinetic considerations on Orgaran (Org 10172) therapy. Haemostasis. 1992;22:73-84.
60. Stiekema JC, Wijnand HP, Van Dinther TG, et al. Safety and pharmacokinetics of the low molecular weight heparinoid Org 10172 administered to healthy elderly volunteers. Br J Clin Pharmacol. 1989;27:39-48.
61. ten Cate H, Henny CP, ten Cate JW, et al. Anticoagulant effects of a low molecular weight heparinoid (Org 10172) in human volunteers and haemodialysis patients. Thromb Res. 1985;39:211-222.
62. Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaran (Org 10172). Thromb Haemost. 1993;70:554-561.
63. Greinacher A, Amiral J, Dummel V, et al. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay. Transfusion. 1994;34:381-385.
64. Hirsh J, Raschke R, Warkentin TE, Dalen JE, Deykin D, Poller L. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety. Chest. 1995;108:258-2755.
65. Greinacher A, Philippen KH, Kemkes-Matthes B, et al. Heparin-associated thrombocytopenia type II in a patient with end-stage renal disease: successful anticoagulation with the low-molecular-weight heparinoid Org 10172 haemodialysis. Nephrol Dial Transplant. 1993;8:1176-1177.
66. Henny CP, ten Cate H, ten Cate JW, et al. Use of a new heparinoid as anticoagulant during acute haemodialysis of patients with bleeding complications. Lancet. 1983;i:891-893.
67. Greinacher A, Drost W, Michels I, et al. Heparin-associated thrombocytopenia: successful therapy with the heparinoid Org 10172 in a patient showing cross-reaction to LMW heparins. Ann Hematol. 1992;64:40-42.
68. Rowlings PA, Mansberg R, Rozenberg MC, Evans S, Murray B. The use of a low molecular weight heparinoid (Org 10172) for extracorporeal procedures in patients with heparin dependent thrombocytopenia and thrombosis Aust N Z J Med. 1991;21:52-54.
69. Massey EW, Biller J, Davis JN, et al. Large dose infusions of heparinoid Org 10172 in ischemic stroke. Stroke. 1990;21:1289-1292.
70. TOAST Investigators. Low molecular weight heparinoid, Org 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. JAMA. 1998;279:1265-1272.
71. Turpie AGG, Gent M, Cote R, et al. A low molecular weight heparinoid compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke. Ann Int Med. 1992;117:353-357.
72. Nieuwenhuis HK, Sixma JJ. Treatment of disseminated intravascular coagulation in acute promyelocytic leukemia with low molecular weight heparinoid Org 10172. Cancer. 1986;58:761-764.
73. Wilhelm MJ, Schmid C, Kececioglu D, et al. Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia using Org 10172. Ann Thorac Surg. 1996;61:920-924.
74. Marshall LR, Cannell PK, Herrmann RP. Successful use of the aPTT in monitoring of the anti-factor Xa activity of the heparinoid Organon 10172 in a case of HITS requiring open heart surgery. Thromb Haemost. 1992;67:587. Letter.
75. Deryck YLJM, Schepp RM, van Krugten RJ, Mochtar B. Heparinoid Org 10172 anticoagulation for cardiopulmonary bypass: a case report. J Cardiothorac Vasc Anesth. 1990;4(suppl 3):40.
76. Magnani HN, Beijering RJR, ten Cate JW, Chong BH. Orgaran anticoagulation for cardiopulmonary bypass in patients with heparin-induced thrombocytopenia. In: Pifarre R, ed. New Anticoagulants for the Cardiovascular Patient. Philadelphia, Pa: Hanley & Belfus, Inc: 1997:487-500.
77. Doherty DC, Ortel TC, de Bruijn N, Greenberg CS, van Trigt P III. "Heparin-free" bypass: first reported use of heparinoid (Org 10172) to provide anticoagulation for cardiopulmonary bypass. Anesthesiology. 1990;734:562-565.
78. Schmahl KS, Ganjoo AK, Karloff MG. Orgaran (Org 10172) for cardiopulmonary bypass in heparin-induced thrombocytopenia: role of adjunctive plasmapheresis. J Cardiothorac Vasc Anesth. 1997;11:262-264.
79. Wallis RB. Hirudins: from leeches to man. Semin Thromb Hemost. 1996; 22:185-196.
80. Turpie AGG, Weitz JI, Hirsh J. Advances in antithrombotic therapy: novel agents. Thromb Haemost. 1995;74:565-571.
81. Eicher P, Olbrich K, Potzsch B, Greinacher A. Anti-hirudin antibodies in patients treated with recombinant hirudin for more than five days, a prospective study. Thromb Haemost. 1997:77(suppl 1):493. Abstract.
82. Meyer BH, Luus HG, Muller FO, Badenhorst PN, Roethig H. The pharmacology of recombinant hirudin, a new anticoagulant. S Afr J Med. 1990;78: 268-270.
83. Agnelli G, Sonaglia F. Recombinant hirudin in the prevention of venous thromboembolism in patients undergoing elective hip surgery. Semin Thromb Hemost. 1997;23:143-148.
84. Vanholder R, Camez A, Veys N, Van Loo A, Dhondt AM, Ringoir S. Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients. Thromb Haemost. 1997;77:650-655.
85. Eriksson BI, Ekman S, Kalebo P, et al. Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet. 1996;347:635-639.
86. Eriksson BI, Wille-Jorgensen P, Kalebo P, et al. A comparison of recombinant hirudin with a low molecular weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med. 1997;337:1329-1335.
87. Parent F, Bridey F, Dreyfus M, et al. Treatment of severe venous thrombo-embolism with intravenous hirudin (HBW 023): an open pilot study Thromb Haemost. 1993;70:386-388.
88. Schiele F, Lindgaerd F, Eriksson H, et al. Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep venous thrombosis of legs; a multicentre prospective dose-ranging randomized trial. Thromb Haemost. 1997;77:834-838.
89. Serruys PW, Herrman JP, Simon R, et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med. 1995;333:757-763.
90. The Global Use of Strategies of Open Occluded Coronary Arteries (GUSTO IIb) Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med. 1996;335:775-782.
91. Antman EM, for the TIMI 9B Investigators. Hirudin in acute myocardial infraction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation. 1996;94:911-921.
92. Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation. Circulation. 1997;96:769-777.
93. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO IIa) Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation. 1994;90:1631-1637.
94. Antman EM. Hirudin in acute myocardial infarction: safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial. Circulation. 1994;90:1624-1630.
95. Neuhaus KL, von Essen R, Tebbe U, et al. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HITMI) study. Circulation. 1994;90:1638-1642.
96. Schiele F, Vuillemenot A, Kramarz P, et al. Use of recombinant hirudin as antithrombic treatment in patients with heparin-induced thrombocytopenia. Am J Hematol. 1995;50:20-25.
97. Riess F, Lower C, Seelig C, et al. Recombinant hirudin as a new anticoagulant during cardiac operations instead of heparin: successful for aortic valve replacement in man. J Thorac Cardiovasc Surg. 1995;110:265-267.
98. Potzch B, Madlener K, Seelig C, et al. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass - assessment of the whole blood ecarin clotting time. Thromb Haemost. 1997;77:902-925.
99. Greinacher A, Volpel H, Potzsch B. Recombinant hirudin in the treatment of patients with heparin-induced thrombocytopenia (HIT). Blood 1996;88(suppl 1B):281A.
100. Tripodi A, Chantarangkul V, Arbini AA, Moia M, Mannucci PM. Effects of hirudin on activated partial thromboplastin time determined with ten different reagents. Thromb Haemost. 1993;70:286-288.
101. Breddin HK, Radziwon P, Boczkowska-Radziwon B. Laboratory monitoring of new antithrombotic drugs. Clin Lab Med. 1994;14:825-846.
102. Nowak G, Bucha E. Quantitative determination of hirudin in blood and body fluids. Semin Thromb Hemost. 1996;22:197-202.
103. Fox I, Dawson A, Loynds P, et al. Anticoagulant activity of hirulog, a direct thrombin inhibitor, in humans. Thromb Haemost. 1993;69:157-163.
104. Ginsberg JS, Nurmohamed MT, Gent M, et al. Use of hirulog in the prevention of venous thrombosis after major hip or knee surgery. Circulation. 1994; 90:2385-2389.
105. Bittle JA, Strony J, Brinker JA, et al. Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or post-infarction angina. N Engl J Med. 1995;333:764-769.
106. Fuchs J, Cannon CP. Hirulog in the treatment of unstable angina: results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial. Circulation. 1995;92:727-733.
107. White HD. Clinical trials of direct thrombin inhibitors in acute ischaemic syndromes. Thromb Haemost. 1997;78:364-366.
108. Chamberlin JR, Lewis B, Leya F, et al. Successful treatment of heparin associated thrombocytopenia and thrombosis using Hirulog. Can J Cardiol. 1995; 11:511-514.
109. Lewis BE, Walenga JM, Waliis DE. Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Semin Thromb Haemost. 1997;23:197-202.
110. Clarke RJ, Mayo G, Fitzgerald GA, Fitzgerald DJ. Combined administration of aspirin and a specific thrombin inhibitor in man. Circulation. 1991;83: 1510-1518.
111. Verstraete M. Direct thrombin inhibitors: appraisal of the antithrombotic/hemorrhagic balance. Thromb Haemost. 1997;78:357-363.
112. Gold HK, Torres FW, Garabedian HD, et al. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. J Am Coll Cardiol. 1993;21: 1039-1047.
113. Lewis BE, Ferguson JJ, Grassman ED, et al. Successful coronary interventions performed with argatroban anticoagulation in patients with heparin-induced thrombocytopenia and thrombosis syndrome. J Invas Cardiol. 1996;8:410-417.
114. Sakamoto S, Hirase T, Suzuki S, et al. Inhibitory effect of argatroban on thrombin-antithrombin III complex after percutaneous transluminal coronary angioplasty. Thromb Haemost. 1995;74:801-802. Letter.
115. Matsuo T, Kario K, Kodama K, Okamoto S. Clinical application of the synthetic thrombin inhibitor, argatroban (MD-805). Semin Thromb Hemost. 1992; 18:155-160.
116. Vermeer F, Vahanian A, Fels PW, Besse D, Radzik D, Simoons ML. Intravenous argatroban versus heparin as co-medication to alteplase in the treatment of acute myocardial infarction: preliminary results of the ARGAMI pilot study. J Am Coll Cardiol. 1997;29:185-186. Abstract.
117. Kario K, Kodama K, Koide M, Matsuo T. Thrombin inhibition in the acute phase of ischaemic stroke using argatroban. Blood Coagul Fibrinolysis. 1995;6: 423-427.